Urinary Bladder Neoplasms

• 

  Subject Areas on Research

  • "Wildcatting" for breakthroughs in urothelial cancer detection and management--a frustrating business. 
  • 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity. 
  • A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. 
  • A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. 
  • A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. 
  • A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. 
  • A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. 
  • A cytotoxic proteinase isolated from human lymphocytes. 
  • A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. 
  • A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. 
  • A new assay to quantify in vivo repair of G:T mispairs by base excision repair. 
  • A novel XPF -357A>C polymorphism predicts risk and recurrence of bladder cancer. 
  • A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. 
  • A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. 
  • A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment. 
  • A systematic review of regional hyperthermia therapy in bladder cancer. 
  • ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer. 
  • ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update. 
  • ACR Appropriateness Criteria® Pretreatment Staging of Muscle-Invasive Bladder Cancer. 
  • Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. 
  • Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. 
  • Activation of cyclophosphamide for in vitro testing of cell sensitivity. 
  • Activities and accomplishments of the cancer and leukemia group B genitourinary committee. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. 
  • Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. 
  • Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. 
  • Anticipatory Positive Urine Tests for Bladder Cancer. 
  • Antigenic activity of human urothelial tissue. 
  • Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. 
  • Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). 
  • Assessment of quality of cancer-related follow-up care from the cancer survivor's perspective. 
  • Assessment of spatial variation of risks in small populations. 
  • Assessments of frailty in bladder cancer. 
  • Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. 
  • Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer. 
  • Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. 
  • Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. 
  • Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer. 
  • Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. 
  • Augmentation and substitution enterocystoplasty. 
  • Automated versus manual analysis of body composition measures on computed tomography in patients with bladder cancer. 
  • Avoiding complications with radical cystectomy. 
  • BK virus-associated urinary bladder carcinoma in transplant recipients: productive or nonproductive polyomavirus infections in tumor cells? 
  • Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. 
  • Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. 
  • Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. 
  • Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Bladder cancer. 
  • Bladder cancer. Clinical guidelines in oncology. 
  • Bladder cancer. Clinical practice guidelines in oncology. 
  • Bladder cancer: chemohyperthermia for bladder cancer--clinically effective? 
  • Bladder cancer: race differences in extent of disease at diagnosis. 
  • Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. 
  • Bladder leiomyoma: advantages of sonography over computed tomography. 
  • CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. 
  • CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 
  • CLT1 targets bladder cancer through integrin α5β1 and CLIC3. 
  • Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. 
  • Carcinogenesis in urogenital sites. 
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. 
  • Cardiac metastasis from a transitional cell carcinoma: a case report. 
  • Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. 
  • Clinical performance and utility of a DNA methylation urine test for bladder cancer. 
  • Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage. 
  • Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. 
  • Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. 
  • Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. 
  • Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. 
  • Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. 
  • Comprehensive handbook for developing a bladder cancer cystectomy database. 
  • Comprehensive molecular characterization of urothelial bladder carcinoma. 
  • Computed tomographic imaging of microscopic dystrophic calcification in urachal adenocarcinoma. 
  • Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing. 
  • Continent urinary diversion. 
  • Critical review of radical cystectomy and indicators of prognosis. 
  • Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. 
  • Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy. 
  • Defective monocyte function in patients with genitourinary carcinoma. 
  • Detection of H-ras mutations in urine sediments by a mutant-enriched PCR technique. 
  • Detection of metastatic tumors in nude mice: brief communication. 
  • Detection of oncornavirus antigenic activity in human urothelial tissues. 
  • Development and application of basic research techniques in bladder cancer research. 
  • Diagnosis of bladder tumor. 
  • Diagnostic tests in urology: urine cytology. 
  • Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer. 
  • Dietary patterns and health-related quality of life in bladder cancer survivors. 
  • Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. 
  • Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. 
  • Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. 
  • Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? 
  • Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? 
  • Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding. 
  • ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. 
  • Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. 
  • Early detection and measurement of urothelial tumors in mice. 
  • Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. 
  • Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. 
  • Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. 
  • En Bloc Resection of Bladder Tumors: Style or Substance? 
  • Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. 
  • Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. 
  • Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. 
  • Evolution of Single-Use Urologic Endoscopy: Benchtop and Initial Clinical Assessment of a New Single-Use Flexible Cystoscope. 
  • Exon 3 polymorphisms and haplotypes of O6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case-control analysis. 
  • Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. 
  • Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. 
  • Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. 
  • From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guérin Trials in Non-muscle-invasive Bladder Cancer. 
  • Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. 
  • Functional polymorphisms of JWA gene are associated with risk of bladder cancer. 
  • G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. 
  • Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. 
  • Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. 
  • Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study. 
  • Geriatric conditions and treatment burden following diagnosis of non-muscle- invasive bladder cancer in older adults: A population-based analysis. 
  • Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration. 
  • Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study. 
  • Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer.THERMODOX®. 
  • Heated Intravesical Chemotherapy: Biology and Clinical Utility. 
  • Hemolytic anemia and metastatic carcinoma: case report and literature review. 
  • Hereditary renal cell carcinoma in the rat associated with nonrandom loss of chromosomes 5 and 6. 
  • Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer? 
  • Hyperthermia as a treatment for bladder cancer. 
  • Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. 
  • ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. 
  • Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. 
  • Impact of bladder cancer on health-related quality of life. 
  • Impact of marital status in patients undergoing radical cystectomy for bladder cancer. 
  • Implications of Cystectomy Travel Distance for Hospital Readmission and Survival. 
  • In vitro chemotherapeutic testing of urologic tumors. 
  • In vitro chemotherapy testing of transitional cell carcinoma. 
  • Incidence and risk factors of stomal complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder cancer. 
  • Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. 
  • Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy. 
  • Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop. 
  • Interpreting a study on bladder cancer screening. 
  • Intracavitary mitomycin-C in the treatment of superficial urothelial tumors: a preliminary report. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. 
  • Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. 
  • Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines. 
  • Intravital optical imaging for immune cell tracking after photoimmunotherapy with plasmonic gold nanostars. 
  • Investigational therapies for non-muscle invasive bladder cancer. 
  • Isolation and characterization of a novel human bladder cancer cell line: BK10. 
  • It May Be Time to Abandon Urine Tests for Bladder Cancer. 
  • Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers. 
  • Laparoscopic hand assisted radical cystectomy with ileal conduit urinary diversion. 
  • Laparoscopy-assisted robotic radical cystoprostatectomy with ileal conduit urinary diversion for muscle-invasive bladder cancer: initial two cases. 
  • Lesions of bone and bladder cancer. 
  • Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review. 
  • Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. 
  • Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. 
  • Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. 
  • Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. 
  • Lymphoepithelioma-like carcinoma of the urinary bladder. 
  • Magnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study. 
  • Maintenance bacillus Calmette-Guérin: why is there continued debate? 
  • Management of patients with concurrent primary tumors of bladder and prostate. 
  • Management of primary squamous cell carcinoma at the mucocutaneous junction of an ileal conduit. 
  • Maximizing outcomes in genitourinary cancers across the treatment continuum. 
  • Methoxyflurane-induced renal dysfunction. 
  • Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms. 
  • Molecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping. 
  • Molecular markers in bladder cancer. 
  • Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. 
  • Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer. 
  • Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? 
  • Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. 
  • N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines. 
  • NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. 
  • NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. 
  • NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. 
  • Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. 
  • National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results. 
  • New and emerging therapies for bone metastases in genitourinary cancers. 
  • Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. 
  • Non-Hodgkin's lymphoma with bladder involvement. 
  • Novel suppressor loci on chromosome 14q in primary bladder cancer. 
  • Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. 
  • Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. 
  • Open surgical partial nephrectomy for upper tract urothelial carcinoma. 
  • Optimal staging procedures, including imaging, to define prognosis of bladder cancer. 
  • Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer. 
  • Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder. 
  • Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. 
  • Overview of bladder cancer trials in the Cancer and Leukemia Group B. 
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 
  • PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. 
  • Partitioning of time trends in prevalence and mortality of bladder cancer in the United States. 
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. 
  • Perioperative Intravesical Chemotherapy for Patients WithNon-Muscle-invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-recommended Use. 
  • Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 
  • Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. 
  • Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. 
  • Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). 
  • Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. 
  • Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience. 
  • Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 
  • Physical activity patterns and associations with health-related quality of life in bladder cancer survivors. 
  • Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). 
  • Post-traumatic stress disorder symptoms in non-muscle-invasive bladder cancer survivors: A population-based study. 
  • Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty. 
  • Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival. 
  • Preoperative immunonutrition prior to radical cystectomy: a pilot study. 
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. 
  • Primary non-urachal adenocarcinoma of the bladder. 
  • Prostatic disorders: MR imaging at 1.5 T. 
  • Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. 
  • Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. 
  • Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. 
  • Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). 
  • Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. 
  • Re: Jiang et al.: Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk (Urology 2010;76:765). 
  • Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012. 
  • Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. 
  • Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. 
  • Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. 
  • Relationships among uncertainty, post-traumatic stress disorder symptoms, and quality of life in non-muscle-invasive bladder cancer survivors. 
  • Reply by Authors. 
  • Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'. 
  • Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. 
  • Response of human urothelium to chemical carcinogens in vitro. 
  • Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. 
  • Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. 
  • Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis. 
  • Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall. 
  • Small cell bladder cancer: should we consider prophylactic cranial irradiation? 
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. 
  • Squamous carcinoma of urinary bladder. 
  • Statistical analysis of cytologic features useful in separation of metastatic urothelial carcinoma from other metastatic epithelial malignancies. 
  • Statistically adjusted estimates of geographic mortality profiles. 
  • Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. 
  • Superficial bladder cancer epidemiology, diagnosis and management. 
  • Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers. 
  • Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? 
  • Systemic chemotherapy for urothelial cancer. 
  • TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. 
  • Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. 
  • The Cost to Medicare of Bladder Cancer Care. 
  • The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. 
  • The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program. 
  • The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy. 
  • The association of oncogenic human papillomaviruses with urologic malignancy. The controversies and clinical implications. 
  • The characteristics of bladder cancer after radiotherapy for prostate cancer. 
  • The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients. 
  • The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. 
  • The histopathology of vesical diverticula. 
  • The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. 
  • The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting. 
  • The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2. 
  • The predictive value of 2,-4, dinitrochlorobenzene skin testing in patients with bilharzial bladder cancer. 
  • The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. 
  • The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. 
  • The role of flow cytometry in the management of bladder cancer. 
  • The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy. 
  • The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. 
  • The use of hyperthermia in the treatment of bladder cancer. 
  • The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. 
  • Thermal dosimetry for bladder hyperthermia treatment. An overview. 
  • Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. 
  • Thromboembolism and bleeding in bladder cancer. 
  • Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma. 
  • Toward improved effectiveness of bladder cancer immunotherapy. 
  • Transitional cell carcinoma in a prostatic remnant 10 years after radical cystectomy. 
  • Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. 
  • Treatment of superficial carcinoma of the bladder. 
  • Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. 
  • Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. 
  • Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. 
  • Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer. 
  • Urologic surgery. 
  • Use of an Electronic Medical Record to Assess Patient-Reported Morbidity Following Ureteroscopy. 
  • Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. 
  • Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma. 
  • VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. 
  • Vaginal Complications after Cystectomy: Results from a Medicare Sample. 
• 

  Keywords of People

  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Inman, Brant Allen, Professor of Surgery, Surgery, Urology